Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination
- PMID: 10588171
- DOI: 10.1016/s0002-9343(99)00078-9
Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination
Abstract
Subgroups of patients with irritable bowel syndrome (IBS) are likely to respond differently to existing and evolving therapies. The following criteria for subgrouping may be considered: (1) Patients with different predominant bowel habits respond differently to treatment (antidepressants, 5HT3-antagonists, psychotherapy). (2) Postprandial exacerbation of pain or other gastrointestinal symptoms is seen in approximately half of patients with IBS and may identify patients who are more responsive to some classes of drugs (e.g., those targeted at motility). (3) Women appear to respond differently from men to 5HT3-antagonists, and there may be gender differences in gastrointestinal physiology. (4) There is more overlap in the diagnosis of functional dyspepsia and IBS than would be predicted by chance, and both are associated with hyperalgesia to intraluminal distention.
Similar articles
-
Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study.Eur J Gastroenterol Hepatol. 1998 May;10(5):415-21. doi: 10.1097/00042737-199805000-00011. Eur J Gastroenterol Hepatol. 1998. PMID: 9619389
-
Is functional dyspepsia just a subset of the irritable bowel syndrome?Baillieres Clin Gastroenterol. 1998 Sep;12(3):443-61. doi: 10.1016/s0950-3528(98)90017-3. Baillieres Clin Gastroenterol. 1998. PMID: 9890081 Review.
-
Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA.Dig Dis Sci. 2008 Jan;53(1):271-6. doi: 10.1007/s10620-007-9853-x. Epub 2007 Jun 5. Dig Dis Sci. 2008. PMID: 17549631
-
Symptomatic presentations of the irritable bowel syndrome.Gastroenterol Clin North Am. 1991 Jun;20(2):235-47. Gastroenterol Clin North Am. 1991. PMID: 2066150 Review.
-
Irritable bowel syndrome: update on pathogenesis and management.Med Princ Pract. 2002 Jan-Mar;11(1):2-17. doi: 10.1159/000048654. Med Princ Pract. 2002. PMID: 12116690 Review.
Cited by
-
Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study.World J Gastroenterol. 2012 May 7;18(17):2067-75. doi: 10.3748/wjg.v18.i17.2067. World J Gastroenterol. 2012. PMID: 22563194 Free PMC article. Clinical Trial.
-
Antibiotics for irritable bowel syndrome: rationale and current evidence.Curr Gastroenterol Rep. 2012 Oct;14(5):439-45. doi: 10.1007/s11894-012-0284-2. Curr Gastroenterol Rep. 2012. PMID: 22945316 Review.
-
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.Gut. 2003 May;52(5):671-6. doi: 10.1136/gut.52.5.671. Gut. 2003. PMID: 12692051 Free PMC article. Clinical Trial.
-
Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials.Nutrients. 2022 Jun 15;14(12):2482. doi: 10.3390/nu14122482. Nutrients. 2022. PMID: 35745212 Free PMC article.
-
Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.Value Health. 2013 Jan-Feb;16(1):97-103. doi: 10.1016/j.jval.2012.08.2207. Epub 2012 Nov 30. Value Health. 2013. PMID: 23337220 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical